ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
ARS Pharmaceuticals, Inc. (SPRY) reported a Q3 loss of $0.20 per share, missing the Zacks Consensus Estimate of a $0.18 loss. This is a larger loss compared to $0.16 per share a year ago.
November 13, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ARS Pharmaceuticals reported a Q3 loss of $0.20 per share, missing the expected loss of $0.18 and increasing from last year's $0.16 loss.
The reported loss per share of $0.20 is worse than both the expected loss of $0.18 and the previous year's loss of $0.16, indicating a negative financial performance. This is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100